Akèy › Limfom Selil-T › Oregon
Etid klinik pou Limfom Selil-T nan Oregon
4 etid pou Limfom Selil-T ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Oregon Health & Science University; Knight Cancer Institute, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Bay Area Hospital, Coos Bay
- ak 6 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06724237MB-105 in Patients With CD5 Positive T-cell Lymphoma
- Oregan Health & Science University, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 3, 2025 · NCT06534060Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Oregon Health & Science University, Portland
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.